| Date | Title | Description |
| 02.09.2026 | Innovation's Edge: Reshaping Our World | Science surges forward. AI transforms drug discovery. Quantum physics redefines reality. Solid-state batteries promise energy revolutions. Medical technology extends life, prints organs, and edits genes. These advancements offer immense opp... |
| 28.08.2026 | Дьявол в мелочах: влияние депрессии на нейрогенез гиппокампа | Одним из самых грубых заблуждений касательно психического здоровья является мысль, что психика не имеет ничего общего с физическим миром, т. е. с органами, тканями и клетками. Любые отклонения или жалобы воспринимаются как выдумки, накручив... |
| 21.08.2026 | lab on a chip technology Market to Reach USD 21.36 Billion by 2030 | The global lab on a chip technology Market is projected to grow from USD 14.01 billion in 2025 to USD 21.36 billion by 2030, registering a CAGR of 8.8% during the forecast period. Market growth is being driven by increasing demand for high-... |
| 10.08.2026 | Heart Transplant Rejection Study Maps Molecular Divide Biopsy Grading Cannot See | By Joseph Blake
Published: Aug 10 2026, 11:00 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 27.07.2026 | Novogene Europe expands single-cell sequencing capability at Cambridge Omics Centre | Offers UK academic, biotech and biopharma researchers direct access to specialist project support, 10x Genomics Chromium Single Cell-based workflows, sequencing infrastructure and bioinformatics expertise
Cambridge, UK, 27 July 2026: Novoge... |
| 15.07.2026 | Biochips Market to Reach $21.36 Billion by 2030 | The global biochips market is projected to grow from USD 14.01 billion in 2025 to USD 21.36 billion by 2030, at a CAGR of 8.8% during the forecast period. Market growth is fueled by increasing demand for faster, more accurate, and cost-effe... |
| 01.06.2026 | Countable Labs Secures $26M to Advance Precision Genomics with Countable PCR | Countable Labs just raised $26 million. This oversubscribed funding round accelerates commercialization of its Countable PCR technology. The platform offers single-molecule quantification, outperforming digital PCR in sensitivity and precis... |
| 28.05.2026 | Countable Labs Raises $26 Million To Accelerate Countable PCR Commercialization | Countable Labs announced it has raised $26 million in an oversubscribed financing round to accelerate clinical product development and global commercialization of its Countable PCR technology.
The financing round was led by ARCH Venture Par... |
| 21.04.2026 | Lightcast Secures Major Funding, Redefines Single-Cell Analysis with Envisia Platform | Lightcast, a life science innovator, secured $27 million in funding. ARCH Venture Partners led the round. This capital fuels the 2026 commercial launch of its Envisia™ benchtop platform. Envisia marks a significant leap in single-cell analy... |
| 14.04.2026 | Lightcast Raises $27 Million and Adds Industry Veteran to Accelerate Commercialization of Envisia™ Platform | · Proceeds will help enhance workflows and expand single-cell functional assay portfolio
· Brad Crutchfield joins as advisor to support early access growth and global launch
CAMBRIDGE, England – April 14, 2026 – Lightcast, a pioneering life... |
| 25.03.2026 | Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs | The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today
The Launch of STELA: Bioptimus is es... |
| 13.02.2026 | Omics Empower Hong Kong Launches Xenium™ In Situ Spatial Transcriptomics Services | HONG KONG, Feb. 13, 2026 /PRNewswire/ -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ Spatial Transcriptomics services are now avail... |
| 20.10.2025 | Anthropic takes aim at biotech with Claude for Life Sciences
Claude Code comes to the web and mobile
Send us a News Tip
EXTRACT THE SIGNAL FROM THE NOISE
Cookies | Anthropic PBC has had a busy start to the week, launching a new tool called Claude for Life Sciences to help with scientific research, and expanding the availability of its Claude Code agentic coding tool to the web and its mobile applicati... |
| 20.10.2025 | Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost | Anthropic announced Claude for Life Sciences, an AI integration for researchers to advance scientific discovery.
Claude for Life Sciences is built around Anthropic’s existing AI models and supports connections with other scientific tools in... |
| 18.09.2025 | Biostate AI Launches K-Dense Beta, an AI Agent That Compresses Research Cycles from Years to Days; Validated with Harvard Longevity Discovery Breakthrough | Biostate AI, a company accelerating biological research through innovative AI models, announced the launch of
Beta, a comprehensive multi-agent AI research system that can compress research cycles from years to days, while eliminating hallu... |
| 10.08.2025 | 10x Genomics to Acquire Scale Biosciences | 10x Genomics, Inc. (Nasdaq: TXG), a Pleasanton, CA-based leader in single cell and spatial biology, is to acquire Scale Biosciences, Inc., a leader in innovative and scalable single cell analysis.
The acquisition will further expand Chromiu... |
| 18.06.2025 | Sphere Bio and Bio-Rad: Pioneering the Future of Life Sciences | In the ever-evolving landscape of life sciences, two companies are making significant strides: Sphere Bio and Bio-Rad Laboratories. Both are expanding their reach and enhancing their product offerings, aiming to meet the growing demands of ... |
| 17.06.2025 | Sphere Bio expands operations in China | Exclusive agreement with specialist biotechnology distributor, Redbert Biotechnology, to strengthen international growth and market penetration
Johnathan Fu appointed as China Distribution Manager to lead regional partnerships and enhance c... |
| 27.05.2025 | Biostate AI: $12 Million Raised For AI And RNA Sequencing Platform | Biostate AI, an innovator in AI and RNA sequencing, announced the completion of a $12 million Series A funding round, led by Accel. And additional investors included Gaingels, Mana Ventures, InfoEdge Ventures, and existing investors Matter ... |
| 21.05.2025 | Biostate AI Raises $12M in Series A Funding | Biostate AI, a Houston, TX-based artificial intelligence and RNA sequencing company, raised $12M in Series A funding.
The round was led by Accel with participation from Gaingels, Mana Ventures, InfoEdge Ventures, Matter Venture Partners, Vi... |
| 21.05.2025 | Biostate AI Raises USD 12 Mn Series A Led by Accel The company plans to deepen its dataset, expand collaborations in oncology, autoimmune, and cardiovascular research, and improve its predictive model... | Biostate AI has raised USD 12 million in a Series A funding round led by Accel, with participation from Gaingels, Mana Ventures, InfoEdge Ventures, and returning investors Matter Venture Partners, Vision Plus Capital, and Catapult Ventures.... |
| 03.09.2024 | Next Generation Sequencing Market is poised to grow from USD 36.04 billion by 2031: Skyquest Technology | Share
Tweet
Share
Share
Email
In recent years, next generation sequencing is a technique that employs massive parallelism in sequencing millions or even billions of DNA strands. This method is also known as high throughput sequencing. NGS i... |
| 29.07.2024 | Predicta Biosciences: Pioneering a New Era in Cancer Diagnostics | Predicta Biosciences is making waves in the ocean of cancer diagnostics. With a fresh infusion of $5.2 million in seed funding, this Boston-based precision oncology company is poised to change the landscape of how we detect and treat blood ... |
| 27.07.2024 | Predicta Biosciences Raises $5.2 Million To Develop Novel Diagnostic And Therapeutic Products | Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, announced it had raised an oversubscribed $5.2 million seed round led by The Engine Ventures. And additional participating investors in... |
| 13.05.2024 | Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK | BURLINGTON, Mass., May 13, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further i... |
| 27.11.2023 | Endothelial cells adopt a pro-reparative immune responsive signature during cardiac injury | Introduction
Heart disease, the leading cause of mortality in the world, results from irreversible cardiomyocyte loss after tissue damage such as ischemic injury (Roth et al, 2020; Virani et al, 2021). Extensive basic, translational, and cl... |
| 08.08.2023 | Loss of smell or taste was once a telltale sign of COVID. Not anymore. | Once a hallmark sign of many COVID-19 cases — sometimes more reliable than even flu-like symptoms at sniffing out people infected by the virus early in the pandemic — was the sudden loss of smell and taste. But growing research suggests thi... |
| 07.08.2023 | Biotech Firm 10X Genomics Is Using Tech To Transform Biology and ‘Advance Human Health’ For All People | 10X Genomics uses technology such as AI to explore and advance spatial biology. Digital Creative Associates |
| 09.12.2022 | 10x Genomics Commercially Launches Xenium Platform for In Situ Analysis | 10x Genomics, Inc. a life sciences leader focused on mastering biology to advance human health, announced the first commercial shipments of its Xenium platform for in situ analysis. Xenium is the next generation of targeted spatial profilin... |
| 21.01.2022 | 10x Genomics Adds Global Clinical Research Organizations to Expanded Certified Service Provider Network | PLEASANTON, Calif., Jan. 21, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the expansion of its 10x Certified Service Provider (CSP) Network to ... |
| 25.02.2021 | 10x Genomics : Showcases Next Wave of Innovations at First Ever Xperience Event | PLEASANTON, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today detailed a slew of new products and announced the acquisition of Copenhagen-based Tetramer Shop at its inaugural Xperience 2021 event, a showcase w... |
| 25.02.2021 | Biotech and healthtech firm Foresite Capital raises $969M new fund | The firm, which now has over $4 billion in assets under management, invests across all stages
The biotech space has been growing in the last few years: according to Pitchbook, the space was on track to see more than $20 billion invested in ... |
| 10.12.2019 | $125 million for Inscripta may usher in the next wave of genetic engineering | In these waning days of the second decade of the twenty-first century, technologists and investors are beginning to lay the foundations for new, truly transformational technologies that have the potential to reshape entire industries and re... |
| 06.12.2019 | Creating a Facebook for cell communication can help treat disease | Everyone, it seems, uses Facebook and LinkedIn these days. Social networking sites make it incredibly easy to find information about people. You can look up new acquaintances, professional contacts, even the author of this article to figure... |
| 12.09.2019 | 10x Genomics Prices Initial Public Offering | 10x Genomics, Inc., a Pleasonton, Calif.-based company that build products combining hardware, chemistry, and software to give single cell and spatial views of biological systems, priced its initial public offering.
Its Class A common stock... |
| 07.01.2019 | 10x Genomics Raises Additional $35m in Series D Funding | 10x Genomics, a Pleasanton, CA-based advanced biology company, raised an additional $35m in Series D funding.
The round, which brings total valuation to $1.28 billion and total financing raised to date to $243m, was led by Meritech Capital ... |
| 07.01.2019 | 10x Genomics adds $35M to its VC haul | 10x Genomics has raked in an additional $35 million in funding through an extension of its series D round, which brought in $50 million last April. The new cash brings the sequencing company’s total financing up to $243 million.
That raise ... |
| 07.01.2019 | Term Sheet — Monday, January 7 | HOPING FOR A MARKET DIP
Happy New Year, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
—
In December, Term Sheet published readers’ business-related predictions for 2019. Many of you predicted a recession... |
| 07.01.2019 | 10x Genomics adds $35M to its VC haul | 10x Genomics has raked in an additional $35 million in funding through an extension of its series D round, which brought in $50 million last April. The new cash brings the sequencing company’s total financing up to $243 million.
Sponsored b... |
| 07.01.2019 | Daily funding roundup - January 7th, 2019 | Synapse Technology raised $6M; Vengo raised $7M; FloWater raised $15M; 10x Genomics raised $35M
Synapse Technology: Synapse uses proprietary deep learning and computer vision systems to modernize the security and defense visual analysis fie... |
| 10.12.2018 | 10x Genomics Acquires Spatial Transcriptomics | 10x Genomics, a Pleasanton, CA—based biotech company, acquired Spatial Transcriptomics, a Stockholm, Sweden-based spatial genomics company.
The amount of the deal was not disclosed.
Led by Joakim Lundeberg, Spatial Transcriptomics offers te... |
| 30.08.2018 | 10x Genomics Acquires Epinomics | 10x Genomics, a Pleasanton, Calif.-based leader in the genomics field, acquired Epinomics, a developer of epigenetics solutions.
The amount of the deal was not disclosed.
The acquisition will give 10x Genomics ATAC-seq technology and fundam... |
| 26.04.2018 | 10x Genomics Completes $50M Series D Financing; $75M Credit Facility | 10x Genomics, a Pleasanton, Calif.-based company focused on accelerating genomic discovery, raised $125m in funding.
The funding included a $50m Series D financing led by Meritech Capital Partners and included new investor Wells Fargo Strat... |
| 17.03.2016 | 10X Genomics nets $55M for next-gen sequencing products | The company’s product suite uses whole genome sequencing, single gene expression analysis and careful exome analysis to unveil new structural variants and haplotypes – thus painting a broader picture of human health. It sells instruments, r... |
| 17.03.2016 | 10x Genomics Closes $55M Series C Financing | 10x Genomics, a Pleasenton, Calif.-based company focused on broadening the application of genomic information, closed a $55m Series C financing.
The round was led by Fidelity Management & Research Company with participation from new inv... |
| 13.01.2015 | The future of next-gen sequencing (and why an Illumina cofounder’s never had his genome mapped) | “It’s just that sequencing isn’t good enough today for many of the applications we’re looking at for future clinical use,” he said.
Stuelpnagel, who now chairs Ariosa Diagnostics, 10X Genomics and the just-acquired Sequenta, spoke this week... |
| 12.01.2015 | 10X Genomics Raises $55.5M in Series B Financing | 10X Genomics, a Pleasanton, CA-based provider of a genomics platform, raised $55.5M in its Series B financing.
The round was led by Foresite Capital Management with participation from Venrock, as well as new and existing investors Paladin C... |
| - | 10X Genomics nets $55M for next-gen sequencing products | 10X Genomics, a Bay Area startup that’s building out extensive next-generation sequencing services, just closed out a $55 million Series C round – meant largely to fuel sales and marketing growth.
Investors include Fidelity Management, Soft... |
| - | Early Google exec got Larry Page’s backing to build a start-up factory focused on saving the planet | David Friedberg worked at Google from 2004 to 2006, and then started Climate Corporation, which he later sold to Monsanto for $1 billion.
He has since been investing in start-ups focused on agriculture, food supply and genomics, and in 2017... |
| - | The future of next-gen sequencing (and why an Illumina cofounder’s never had his genome mapped) | John Stuelpnagel – one of Illumina‘s cofounders – has never had his genome sequenced.
“I didn’t feel the need,” Stuelpnagel said.
It’s not because of the cost, nor the fear he’s got some genetic disorder. It’s not even because he believes i... |
